Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Apr 02, 2020

Fulcrum Therapeutics Provides Business Update on Impact of COVID-19

Mar 24, 2020

Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Mar 05, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results

Feb 28, 2020

Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020

Feb 26, 2020

Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Feb 25, 2020

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Thursday, March 5, 2020 at 8:00 a.m. ET

Feb 20, 2020

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Jan 29, 2020

Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio

Jan 06, 2020

Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors

Investor Tools

Privacy Policy
EU Privacy Policy
Terms of Use

Twitter
LinkedIn
Instagram

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact